Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Staffline returns to pre-tax profit in FY24

(Sharecast News) - Recruitment firm Staffline said on Tuesday that it had returned to pre-tax profit in FY24 as revenues neared £1.0bn. Staffline said pre-tax profits came to £5.0m during the period, compared to FY23's pre-tax loss of £2.1m, while gross profits were up 10.3% at £70.8m.

Revenues rose 14% to £992.9m due to market share gains and the increase in the National Living Wage, while gross profit margins slipped just 0.3 percentage points to 7.1% and underlying earnings surged 26% to £12.6m.

Staffline highlighted that increased volumes came from key food retailers such as Tesco, Sainsbury's, Morrisons and Marks & Spencer, combined with increased market share from the logistics sector.

However, Staffline noted that headwinds caused by the proposed increases in employers' national insurance rates have reduced business confidence, which has made it "cautious about prospects" for FY25.

Chief executive Albert Ellis said: "There is no question that the recruitment market remains challenging but the combination of Staffline's extensive scale and reach, market leadership and strong brand has ensured we continue to outperform in an uncertain market, remaining the trusted partner of choice."

As of 0855 BST, Staffline shares were up 0.82% at 30.85p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.